Crossref

1. Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials

- Zeyu Wang

- Huiqing Du

- Ying Zhao

- Yadi Ren

- Cuihua Ma

- Hongyu Chen

- Man Li

- Jiageng Tian

- Caihong Xue

- Guangfeng Long

- Meidong Xu

- Yong Jiang

2. Mechanistic Insights into the Pharmacological Significance of Silymarin

- Karan Wadhwa

- Rakesh Pahwa

- Manish Kumar

- Shobhit Kumar

- Prabodh Chander Sharma

- Govind Singh

- Ravinder Verma

- Vineet Mittal

- Inderbir Singh

- Deepak Kaushik

- Philippe Jeandet

3. Effects of silymarin supplementation in late pregnancy and lactation on reproductive performance, colostrum quality, blood biochemistry and inflammation levels of sows

- Guanglei Cong

- Shuangshuang Xia

- Chunxue Liu

- Junbo Li

- Ifen Hung

- Lili Zhang

- Shuaipeng Guo

- Bo Zhao

4. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review

- Alessio Aghemo

- Olga P. Alekseeva

- Francesco Angelico

- Igor G. Bakulin

- Natalia V. Bakulina

- Dmitry Bordin

- Alexey O. Bueverov

- Oxana M. Drapkina

- Anton Gillessen

- Elvira M. Kagarmanova

- Natalia V. Korochanskaya

- U. A. Kucheryavii

- Leonid B. Lazebnik

- Maria A. Livzan

- Igor V. Maev

- Anatolii I. Martynov

- Marina F. Osipenko

- Evgenii I. Sas

- Antonina Starodubova

- Yurii P. Uspensky

- Elena V. Vinnitskaya

- Emilia P. Yakovenko

- Alexey A. Yakovlev

5. Iron Status and Metabolic Syndrome in Patients with Non-Alcoholic Fatty Liver Disease

- Mohammad Ebrahim Ghamarchehreh

- Nematollah Jonaidi-Jafari

- Mohammad Bigdeli

- Hossein Khedmat

- Amin Saburi

6. Effects of Silybum marianum, Pueraria lobate, combined with Salvia miltiorrhiza tablets on non-alcoholic fatty liver disease in adults: A triple-blind, randomized, placebo-controlled clinical trial

- Bang-yan Li

- Yue Xi

- Yu-Ping Liu

- Di Wang

- Cheng Wang

- Chao-gang Chen

- Xiao-hong Fang

- Zhong-xia Li

- Yu-ming Chen

7.

8. Silybin Modulates Collagen Turnover in an In Vitro Model of NASH

- Beatrice Anfuso

- Pablo J. Giraudi

- Claudio Tiribelli

- Natalia Rosso

9. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease

- Krzysztof Kurek

- Dominika M. Piotrowska

- Patrycja Wiesiołek‐Kurek

- Bartłomiej Łukaszuk

- Adrian Chabowski

- Jan Górski

- Małgorzata Żendzian‐Piotrowska

10. The potential of silymarin for the treatment of hepatic disorders

- Claus Hellerbrand

- Jörn M. Schattenberg

- Philipp Peterburs

- Anja Lechner

- Reto Brignoli

11. Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis

- Schohraya Spahis

- Edgard Delvin

- Jean-Michel Borys

- Emile Levy

12. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?

- Matteo Tacelli

- Ciro Celsa

- Bianca Magro

- Aurora Giannetti

- Grazia Pennisi

- Federica Spatola

- Salvatore Petta

13. Isolation and purification of diastereoisomeric flavonolignans from silymarin by binary‐column recycling preparative high‐performance liquid chromatography

- Weiquan Zhao

- Guang Yang

- Fanyi Zhong

- Nan Yang

- Xin Zhao

- Yunpeng Qi

- Guorong Fan

14. Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials

- Hao Wang

- Qianqian Ma

- Youpeng Chen

- Ling Luo

- Junzhao Ye

- Bihui Zhong

15. Hepatocellular Interactions of Potential Nutraceuticals in the Management of Inflammatory NAFLD

- Devaraj Ezhilarasan

- Kulanthaivel Langeswaran

16. An update on nonalcoholic fatty liver disease

- Daniel M. Provencher

17. Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway

- Qiang Ou

- Yuanyuan Weng

- Siwei Wang

- Yajuan Zhao

- Feng Zhang

- Jianhua Zhou

- Xiaolin Wu

18. State of the art

- Michelle Pearlman

- Rohit Loomba

19. Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: Role of LPS/TLR4 and autophagy pathways

- Lamiaa A. Ahmed

- Maha B. Salem

- Sayed H. Seif el-Din

- Naglaa M. El-Lakkany

- Hend O. Ahmed

- Sami M. Nasr

- Olfat A. Hammam

- Sanaa S. Botros

- Samira Saleh

20. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis

- Oluyemi Komolafe

- Elena Buzzetti

- Audrey Linden

- Lawrence MJ Best

- Angela M Madden

- Danielle Roberts

- Thomas JG Chase

- Dominic Fritche

- Suzanne C Freeman

- Nicola J Cooper

- Alex J Sutton

- Elisabeth Jane Milne

- Kathy Wright

- Chavdar S Pavlov

- Brian R Davidson

- Emmanuel Tsochatzis

- Kurinchi Selvan Gurusamy

21. Efficacy of Hypoglycemic Agents in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): A Systematic Review and Network Meta‐Analysis

- Qiao Ren

- Yao Tan

- Guixiang Zhang

- Yuzhao Dai

- Lidan Yang

- Yunmo Wu

- He He

- Jie Chen

22. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism

- Samir Rouabhia

- Natasa Milic

- Ludovico Abenavoli

23. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD)

- Rosa Lombardi

- Simona Onali

- Douglas Thorburn

- Brian R Davidson

- Kurinchi Selvan Gurusamy

- Emmanuel Tsochatzis

24. Comparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis

- Dachuan Jin

- Zhongfeng Cui

- Shunqin Jin

- Tao Zhou

- Baoqiang Guo

- Peng Gao

- Guangming Li

25. Impact of Silymarin Supplements on Liver Enzyme Levels: A Systematic Review

- Ernesto Calderon Martinez

- Domenica Herrera

- Saruveish Mogan

- Zainab Hameed

- Ayesha Altaf Jangda

- Tayyaba J Khan

- Palvi Mroke

- Samar Sajid

- Yash R Shah

- Imran Baig

26. Har silibinin en plass i behandlingen av leversykdommer?

- Gülen Arslan Lied

- Odd Helge Gilja

- Trygve Hausken

27. Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis

- Jingxuan Lian

- Jianfang Fu

28. Natural Products for the Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review

- Saverio Nucera

- Rosa Maria Bulotta

- Stefano Ruga

- Rosamaria Caminiti

- Maria Serra

- Roberto Bava

- Fabio Castagna

- Carmine Lupia

- Mariangela Marrelli

- Filomena Conforti

- Giancarlo Statti

- Vincenzo Mollace

- Ernesto Palma

29. Protective Effects of Silymarin Against D-Gal/LPS-Induced Organ Damage and Inflammation in Mice

- Xin Zhao

- Haoxiang Wang

- Yue Yang

- Yuting Gou

- Zhiying Wang

- Dingyi Yang

- Chong Li

30. Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations

- Anton Gillessen

- Francesco Angelico

- Jun Chen

- Lungen Lu

- Maria Isabel Lucena

- Qingchun Fu

- Qing Xie

- Raul J. Andrade

- Wen Xie

- Xiaoyuan Xu

- Yanyan Yu

- Yi-min Mao

- Yuemin Nan

31. Expert Opinion on the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Middle East with a Focus on the Use of Silymarin

- Ahmed Hashem

- Yogesh Shastri

- Malfi Al Otaibi

- Elwin Buchel

- Hussam Saleh

- Reyaz Ahmad

- Hamouda Ahmed

- Fateh Al Idris

- Saleh Ahmed

- Mohamed Guda

- Anton Gillessen

32. Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis

- Camila Ribeiro de Avelar

- Emile Miranda Pereira

- Priscila Ribas de Farias Costa

- Rosângela Passos de Jesus

- Lucivalda Pereira Magalhães de Oliveira

33. Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease

- Malek Yaghoubi

- Sattar Jafari

- Behnam Sajedi

- Sepehr Gohari

- Samira Akbarieh

- Amir H. Heydari

- Maryam Jameshoorani

34. Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial

- Manouchehr Khoshbaten

- Samineh Beheshtirouy

- Shahrzad Shayanrad

- Afshin Gharekhani

- Haleh Rezaee

35. Effects of a low-fat diet on the hepatic expression of adiponectin and its receptors in rats with NAFLD

- Hong Ma

- Guo-Ping You

- Fan Cui

- Lu-Fang Chen

- Xiang-Jiu Yang

- Li-Gang Chen

- Hua-Dong Lu

- Wen-Qiang Zhang

36. Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats

- Tewodros Mengesha

- Natesan Gnanasekaran

- Tsegaye Mehare

37. Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury

- Kasra Shahsavari

- Shireen Shams Ardekani

- Mohammad Reza Shams Ardekani

- Majid Mokaber Esfahani

- Hossein Kazemizadeh

- Tannaz Jamialahmadi

- Mehrdad Iranshahi

- Mahnaz Khanavi

- Maede Hasanpour

38. A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease

- Laleh Mahmoudi

- Sara Asadi

- Zahra Al-Mousavi

- Ramin Niknam

39. The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups

- Shiv Chitturi

- Vincent Wai‐Sun Wong

- Wah‐Kheong Chan

- Grace Lai‐Hung Wong

- Simon Kin‐Hung Wong

- Jose Sollano

- Yen‐Hsuan Ni

- Chun‐Jen Liu

- Yu‐Cheng Lin

- Laurentius Adrianto Lesmana

- Seung Up Kim

- Etsuko Hashimoto

- Masahide Hamaguchi

- Khean‐Lee Goh

- Jiangao Fan

- Ajay Duseja

- Yock Young Dan

- Yogesh Chawla

- Geoff Farrell

- Henry Lik‐Yuen Chan

40. Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis,,

- Cai-yan Zou

- Yan Sun

- Jun Liang

41. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

- Han Ah Lee

- Young Chang

- Pil Soo Sung

- Eileen L. Yoon

- Hye Won Lee

- Jeong-Ju Yoo

- Young-Sun Lee

- Jihyun An

- Do Seon Song

- Young Youn Cho

- Seung Up Kim

- Yoon Jun Kim

42. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review

- Maria Zachou

- Pagona Flevari

- Narjes Nasiri-Ansari

- Constantinos Varytimiadis

- Evangelos Kalaitzakis

- Eva Kassi

- Theodoros Androutsakos

43. Effects of silymarin on metabolic syndrome: a review

- Maryam Vahabzadeh

- Nafise Amiri

- Gholamreza Karimi

44. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome

- Peter Dietrich

- Claus Hellerbrand

45. Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis

- Yi-Zhou Huang

- Gang-Yi Yang

- Cong Wang

- Xing-Yu Chen

- Li-Li Zhang

46. Lactobacillus rhamnosus GG Combined with Metformin Alleviates Alcohol-Induced Liver Inflammation in Mice by Maintaining the Intestinal Barrier and Regulating Treg/Th1 Cells

- Yin Zhu

- Yizhi Pan

- Xiaozhi Wang

- Li Wei

- Lujian Zhu

- Yu Guo

- HaoRan Jin

- Yingying Gu

- Yaqin Wang

- Yongping Chen

- Lanman Xu

47. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis

- Chen Ding

- Yaxin Tang

- Wenqiang Zhu

- Piaopiao Huang

- Pingan Lian

- Juanli Ran

- Xiansheng Huang

48. Sylimarin: Traditional and New Effects

- Н.Н. Силивончик

- Т.Н. Якубчик

49. Clinical efficacy of Silybum marianum seed extract in treatment of type 2 diabetes mellitus and non-alcoholic fatty liver disease: a narrative review

- Sayed Mohammad Mohammadi

- Saeed kianbakht

- Shamsali Rezazadeh

- Mojtaba Ziaee

- Hasan Fallah Huseini

50. Non-Alcoholic Fatty Liver Disease (NAFLD): The Search for a Cure

- Alabagi Abdulla

- Charity Reynolds

- H Hesham A-Kader

51. Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis

- Adnan Malik

- Muhammad Malik

- Shahbaz Qureshi

52. Should We Rely on the Findings of Each Published Randomized Controlled Study?

- Ali Kabir

53. Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes (在一种与人类肥胖以及糖尿病相关的动物模型肥沙鼠中，水飞蓟素具有拮抗代谢综合征进展、拮抗氧化应激增加以及拮抗肝脏脂肪变性的有益作用)

- Saida Bouderba

- Carlos Sanchez‐Martin

- Gloria R. Villanueva

- Dominique Detaille

- E. Ahmed Koceïr

54. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic

- Kareem Hassan

55. Non-alcoholic fatty liver disease: need for a balanced nutritional source

- Jayagopalan Veena

- Anjaneyulu Muragundla

- Srinivas Sidgiddi

- Swaminathan Subramaniam

56. Metformin and Probiotics Interplay in Amelioration of Ethanol-Induced Oxidative Stress and Inflammatory Response in an In Vitro and In Vivo Model of Hepatic Injury

- Farhin Patel

- Kirti Parwani

- Dhara Patel

- Palash Mandal

- Muthuraju Sangu

57. Association of Serum Ferritin and Inflammatory Biomarkers with Insulin Resistance in Chinese Type 2 Diabetes Mellitus Patients

- P Paudel

- S Zhang

- B Guo

- A Pannu

- G Rasalingam

- R Sah

- B Desai

- A Yin

- C Gu

- Y Yuan

- L Chen

- W Niu

58. Benefits of Combining Sonchus brachyotus DC. Extracts and Synbiotics in Alleviating Non-Alcoholic Fatty Liver Disease

- Wenwu Huang

- Boyuan Shen

- Xiumei Li

- Tongcun Zhang

- Xiang Zhou

59. Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study

- Fu Jianfang

- Xiao Wanxia

- Gao Xiling

- Xu Jing

- Yang Wenjuan

- Liu Jianrong

- He Qingzhen

- Ma Kaiyan

- Lian Jingxuan

- Chen Taixiong

- Xu Qian

- Li Mengying

- Ming Jie

- Ji Qiuhe

- Ferdinando Carlo Sasso

60. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease

- Swaytha Ganesh

- Vinod K. Rustgi

61.

62. Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD

- Brandon J. Perumpail

- Andrew A. Li

- Umair Iqbal

- Sandy Sallam

- Neha D. Shah

- Waiyee Kwong

- George Cholankeril

- Donghee Kim

- Aijaz Ahmed

63. Effects of silymarin on insulin resistance and sensitivity: A systematic review and meta-analysis of randomized controlled trials

- Shao Yin

- Fengya Zhu

- Ying Liu

- Qiu Chen

64. Future therapy for non‐alcoholic fatty liver disease

- Danny Issa

- Vaishali Patel

- Arun J. Sanyal

65. Silymarin Modulates Microbiota in the Gut to Improve the Health of Sow from Late Gestation to Lactation

- Shengyu Xu

- Xiaojun Jiang

- Xinlin Jia

- Xuemei Jiang

- Lianqiang Che

- Yan Lin

- Yong Zhuo

- Bin Feng

- Zhengfeng Fang

- Jian Li

- Jianping Wang

- Zhihua Ren

- De Wu

66. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis

- Chan Wah Kheong

- Nik Raihan Nik Mustapha

- Sanjiv Mahadeva

67. Effects of different natural products in patients with non‐alcoholic fatty liver disease—A network meta‐analysis of randomized controlled trials

- Hongshuai Liu

- Yufei Li

- Yan Jin

- Xin Li

- Dongxian Wang

- Xiaowen Yu

- Zhenyuan Jiang

- Guoliang Yin

- Suwen Chen

- Xin Zhang

- Decheng Meng

- Wenfei Yu

- Wenyin Jiang

- Fengxia Zhang

68. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease

- Sheng Zhong

- Yuxiang Fan

- Qi Yan

- Xingyu Fan

- Bo Wu

- Yujuan Han

- Ying Zhang

- Yong Chen

- Huimao Zhang

- Junqi Niu

69. Silybin induces endothelium-dependent vasodilation via TRPV4 channels in mouse mesenteric arteries

- Xin Wen

- Yidi Peng

- Bohao Zheng

- Shaying Yang

- Jing Han

- Fan Yu

- Tingting Zhou

- Li Geng

- Zhiming Yu

- Lei Feng

70. Sirt1 and Sirt6 Mediate Beneficial Effects of Rosiglitazone on Hepatic Lipid Accumulation

- Soo Jin Yang

- Jung Mook Choi

- Eugene Chang

- Sung Woo Park

- Cheol-Young Park

- Aimin Xu

71. Temporal Relationship between Diet-Induced Steatosis and Onset of Insulin/Leptin Resistance in Male Wistar Rats

- Li Zhang

- Haiyan Song

- Yingli Ge

- Guang Ji

- Zemin Yao

- Julie A. Chowen

72. Silymarin suppresses HepG2 hepatocarcinoma cell progression through downregulation of Slit-2/Robo-1 pathway

- Nuriye Ezgi Bektur Aykanat

- Sedat Kacar

- Serife Karakaya

- Varol Sahinturk

73.

74. Effect of Medicinal Plants and Natural Products on Liver Enzymes in Non-alcoholic Fatty Liver Patients in Iran

- Moloud Fakhri

- Hafez Fakheri

- Mohammad Azadbakht

- Mahmood Moosazadeh

- Seyde Sedighe Yousefi

75. Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?

- Swetha Rudraiah

- Xi Zhang

- Li Wang